The US FDA is partnering with a prominent rare disease advocate to increase the patient voice in drug approval and development in what appears to be another evolution in the agency's patient-focused drug development efforts.
A new memorandum of understanding (MOU) with the National Organization for Rare Disorders will allow collaboration to plan workshops,...







